← Back to Home

Targeting the source of cerebrospinal fluid: A gene vector reduces brain edema in mice with hydrocephalus

An experimental strategy targeting the choroid plexus reduced brain tissue edema in mice with hydrocephalus, but also reduced some immature neural cells. This proof of concept reveals therapeutic potential while leaving the challenge of protecting normal brain function unresolved.

By SURL BioNews

The damage caused by hydrocephalus extends beyond the enlargement of ventricles by accumulated fluid; edema caused by fluid entering surrounding brain tissue may also worsen injury. Researchers at the University of Cincinnati and the University of California, Davis, attempted to intervene at the source of cerebrospinal fluid production and reduced this type of edema in mice. However, the results also showed that reducing the fluid supply may affect the generation of neural cells.

The study was published on September 29 in *Fluids and Barriers of the CNS*. The team targeted the choroid plexus epithelium within the ventricles. These cells produce cerebrospinal fluid, which provides protection and also carries signals that influence neural cells. Whether reducing fluid-producing tissue can deliver therapeutic benefits while preserving normal physiological function is therefore the central question of this strategy.

The study used an adeno-associated viral vector called AAV5-CMV-DTR to make target cells express the diphtheria toxin receptor, then used diphtheria toxin to induce cell ablation. This method uses gene delivery to establish a controllable experimental tool; injecting the virus alone does not treat hydrocephalus. The study also compared another genetic mouse model. Increasing the toxin dose on postnatal days 3 to 5 slightly reduced cerebrospinal fluid but caused the mouse pups to die.

In the kaolin-induced hydrocephalus experiment, mice first received a vector injection. The disease was induced 10 days later, and toxin treatment began 6 to 10 hours after that. Magnetic resonance imaging showed that choroid plexus ablation reduced brain parenchymal edema and abnormally high signal intensity in the corpus callosum. However, ventricular enlargement did not improve significantly. This means that the imaging benefits occurred primarily in the surrounding tissue and cannot be directly interpreted as a reversal of hydrocephalus.

A safety signal emerged from the neural cell analysis. After reductions in the choroid plexus and cerebrospinal fluid, neuroblasts in the subventricular zone decreased significantly, with a more modest decline in regions associated with the hippocampus. These changes in immature neural cells suggest that normal neurogenesis may be affected. However, the study did not directly conduct cognitive testing, so these findings cannot yet establish impairment of learning or memory.

Several key questions remain before clinical translation. The experiment delivered the vector before disease induction and initiated ablation at an early stage, so it cannot demonstrate that the same method could address human hydrocephalus that has persisted for some time. The vector’s effects on the human choroid plexus, the possibility of effects on non-target cells, and the long-term consequences for neural function all require further evaluation.

The paper also disclosed that Aleksandr Taranov and Yu Luo are co-inventors on a patent application for the related therapeutic strategy. The current evidence supports proof of concept at the animal level. The next priority is to determine the degree of intervention needed to reduce injury from fluid accumulation while retaining enough choroid plexus and cerebrospinal fluid to maintain normal brain function.

References

  1. University of Cincinnati
  2. Fluids and Barriers of the CNS
  3. PubMed — National Library of Medicine